OrbusNeich( http://www.orbusneich.com ) today announced that the company s Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an investigator-initiated randomized study, were published in the June issue of Minerva Cardioangiologica( http://www.minervamedica.it/en/journals/minerva-cardioangiologica/article.php?cod=R05Y2013N03A0301 ).
Claret Medical has announced the publication of an original manuscript by Nicolas Van Mieghem et al—“Histopathology of embolic debris captured during transcatheter aortic valve implantation [TAVI]”. The research was published ahead of print in Circulation on 7 May. The research is the result of collaboration between Erasmus Medical Center, Rotterdam, the Netherlands, and the pathology team of Renu Virmani of the Cardiovascular Pathology Institute, Gaithersburg, USA.
Final 6 and 12-month results of the DIRECT first-in-man clinical study were presented by study principal investigator Dr. Mark Webster at the late-breaking clinical trials session of the EuroPCR meeting yesterday in Paris, France. No patients experienced clinically-driven TLR, TVR or MACE at 6-months, with results sustained through 12-months. It is believed the Svelte drug-eluting stent is the first ever to achieve 0% clinically-driven MACE through 12-months in a independent core-lab and DSMB adjudicated clinical study.
CID SpA have sponsored a symposium at EuroPCR called “Cre8: Welcome back confidence in short dual antiplatelet therapy with effective DES”. The clinical impact of the Demonstr8 data related to Cre8 polymer-free drug-eluting stent is expected to be discussed by the panelists. Chairpersons of the symposium are R Mehran, director of Interventional Cardiovascular Research and Clinical Trials at The Mount Sinai School of Medicine in New York (USA), and O Pachinger, chair of the Department of Cardiology at Medical University of Innsbruck (Austria
Abbott has announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System. Xience Xpedition 48, according to a company release is available in 48mm which is currently the longest stent.
Abbott (ABT) today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). XIENCE Xpedition 48 leverages the proven design and clinical outcomes of the XIENCE family of drug eluting stents in a unique 48 mm length. Abbott continues to offer physicians more options for the treatment of patients with complex coronary artery disease and is the only major manufacturer to offer a coronary drug eluting stent greater than 38 mm in length. XIENCE Xpedition 48 is the latest in a long history of stent innovations pioneered by Abbott, which was the first company to offer physicians size-specific metallic stents for use in small and large vessels of the heart.
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard Embolic Protection Stent (EPS) outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients. Results from the trial were presented at the InspireMD STEMI Symposium at EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI) taking place in Paris from May 21-24, 2013.
Cardiovascular Systems is expected to present late-breaking data from its ORBIT II study of coronary artery disease at EuroPCR in Paris, France, 21–24 May.
On the 21 May 2013 at EuroPCR, Paris, France, one-year results from SOURCE XT (one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date) has reported good clinical outcomes in routine clinical practice, with high rates of device success for all access approaches, valve sizes and delivery systems.
Neovasc Inc. (NVC.V), a developer of novel technologies to treat vascular disease, today reported initial data from open label patient Registries that are tracking the progress of refractory angina patients implanted with the Neovasc ReducerTM, a novel percutaneous device that is CE marked in the European Union for the treatment of refractory angina. The data were presented at EuroPCR 2013, the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013 in Paris, France (21–24 May).
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today excellent long-term results of its CE Mark-approved DESyne® BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating compared to the control Endeavor Zotarolimus Eluting Coronary Stent System with durable coating in the EXCELLA BD randomized clinical trial at the 2-year endpoint.
En un estudio sobre miles de pacientes que habían tenido un infarto, los que recordaron haber tenido un brote de ira el año anterior eran dos veces más propensos a haber tenido el infarto dentro de las dos horas posteriores que en otros momentos de ese año. "Existe un aumento transitorio del riesgo de padecer un infarto después de un brote de ira", dijo la autora principal, Elizabeth Mostofsky, investigadora postdoctoral de la Unidad de Investigación Epidemiológica Cardiovascular de la Facultad de Medicina de Harvard, Boston.
The delayed healing of the coronary artery following implantation of of drug-eluting stents, which increases patients’ risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey announced at EuroPCR 2013 in Paris, France (21–24 May).
OrbusNeich today announced that the companys Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an investigator-initiated randomized study, were published in the June issue of Minerva Cardioangiologica.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos